Fig. S3.

Dose escalation study of TPZ combined with transient L-HAL in precancerous liver of the HBx transgenic mice. Mice were treated with 0.9% saline and two doses of TPZ, 3 and 6 mg/kg, through tail vein injection before transient L-HAL. (A) Transient L-HAL cannot induce hypoxia in the left liver lobe of precancerous HBx transgenic mice. The green arrows indicate the time of L-HAL, and the red arrows indicate the time of L-HAL release. Body weight changes (B), total bilirubin changes (C), and ALT level changes (D) during follow up. (E) Representative H&E staining results of livers from each group of mice harvested at day 1 (Upper) and day 7 (Lower) after treatment. (Scale bars: 0.2 mm.)